Osimertinib Extended OS in EGFR-Mutated Advanced NSCLC
The third-generation drug performed better than erlotinib or gefitinib, according to researchers.
The third-generation drug performed better than erlotinib or gefitinib, according to researchers.
Repeat biopsies may be needed prior to patient inclusion in targeted-therapy trials.
Genetic testing provided important information beyond personal and family history.
Some health care insurers have stopped covering this FDA-approved genetic test, instead limiting coverage only for cheaper, lower-quality genetic tests.
Researchers argue that combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated across cancer types.
Patients whose treatment was based on the molecular characteristics of their particular tumor had significantly better outcomes compared with patients who did not.